Production of the first registered COVID-19 vaccine in the world
The Sputnik V vaccine, developed by the Gamaleya National Research Institute of Epidemiology and Microbiology, was registered by the Ministry of Health of Russia and became the world’s first registered vaccine against coronavirus.
Sputnik V is based on a safe and tested human adenovirus vector platform. Using two different human adenoviral vectors is a unique approach that allows to boost the immune response and provide long lasting immunity.
The efficacy of the Sputnik V vaccine is 91.4%, based on the second interim analysis of data obtained 28 days after administering the first dose (7 days after the second dose).
RDIF jointly with partners and manufacturers is ramping up the production of Sputnik V. The cost of one dose of the vaccine for international markets will be less than $10 (Sputnik V is a two dose vaccine). The lyophilized (dry) form of the vaccine can be stored at a temperature of +2 to +8 degrees Celsius.
Requests for more than 1.2 billion doses of the Sputnik V vaccine came from more than 50 countries. The vaccine supplies for the global market will be produced by RDIF’s international partners in India, Brazil, China, South Korea and other countries.
After the Sputnik V vaccine’s clinical trial preliminary results showed its efficacy at above 90 percent, the Russian Direct Investment Fund and Gamaleya Institute on November 23, 2020 offered AstraZeneca to use one of the two components (human adenoviral vectors) of the Sputnik V vaccine in AstraZeneca’s clinical trials.
AstraZeneca accepted RDIF’s proposal and will begin clinical trials of its vaccine in combination with Sputnik V’s human adenoviral vector type Ad26 by the end of 2020. This research will allow AstraZeneca’s scientists to study the possibility of boosting their vaccine’s efficacy through the application of this combined approach.
For more information visit sputnikvaccine.com and follow Sputnik V on social networks.